Loading organizations...
§ Private Profile · San Diego, CA, USA
Biotechnology company developing iPSC-derived neuron replacement cell therapies for neurological disorders, focused on Parkinson's disease.
Kenai Therapeutics, a San Diego-based biotech company, develops allogeneic neuron replacement cell therapies using iPSC technology for neurological disorders, specifically Parkinson’s disease. Its lead candidate, RNDP-001, an iPSC-derived dopamine progenitor cell therapy, aims to replace lost neurons, with preclinical data showing robust survival and behavioral rescue. It recently secured $82 million in Series A financing from Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group to fund RNDP-001's IND submission and Phase I trials, expected in 2024. The company has already dosed its first patient. Led by CEO Nick Manusos and CTO Derek Hei, and founded by scientific pioneers Howard Federoff and Jeffrey H. Kordower, Kenai emerged from stealth in 2024. Its business model centers on venture capital-funded biotech developing therapies for clinical trials, raised funding to advance lead candidate through proof-of-concept and early clinical stages.
Kenai Therapeutics has raised $86.0M across 2 funding rounds.
Kenai Therapeutics has raised $86.0M in total across 2 funding rounds.
Kenai Therapeutics has raised $86.0M across 2 funding rounds. Most recently, it raised $82.0M Series A in February 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2024 | $82M Series A | Cure Ventures, The Column Group, Alaska Permanent Fund | Euclidean Capital, Saisei Ventures | Announced |
| Feb 14, 2023 | $4M Grant | California Institute For Regenerative Medicine | — | Announced |
Kenai Therapeutics has raised $86.0M in total across 2 funding rounds.
Kenai Therapeutics's investors include Cure Ventures, The Column Group, Alaska Permanent Fund, Euclidean Capital, Saisei Ventures, California Institute for Regenerative Medicine.
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic neuron replacement therapies using induced pluripotent stem cell (iPSC) technology to treat neurological disorders, primarily Parkinson's disease.[1][2][3] Its lead candidate, RNDP-001, targets moderate to moderate-severe idiopathic Parkinson's by replacing lost dopamine neurons for disease-modifying effects, with additional programs like RNDP-002 and RNDP-003 in discovery for inherited subtypes and other conditions.[2][3][4] Founded in 2022 (formerly Ryne Bio), the company has raised $89M total, including an $82M Series A, and serves clinical research, regenerative medicine, and neurological health sectors, showing strong growth via IND preparations, Phase 1/2 trials starting in 2025, and a new San Diego research facility.[1][3][4]
Kenai Therapeutics emerged from stealth in 2024 as a rebranded entity from Ryne Bio, founded in 2022 in Cambridge, Massachusetts, later shifting headquarters to San Diego, California.[1][2][3] Key figures include CEO Nick Manusos, scientific co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower—industry veterans in neuroscience—and board chair Jeff Jonas from Cure Ventures, bringing expertise in CNS disorders and cell therapy.[3] The idea stemmed from leveraging Nobel Prize-winning iPSC platforms for scalable neuron replacement, backed by an exclusive manufacturing partnership with FUJIFILM Cellular Dynamics for cryopreserved production; early momentum came from $82M Series A funding co-led by Alaska Permanent Fund Corporation, The Column Group, and Cure Ventures, enabling preclinical success and IND filing for RNDP-001.[1][2][3]
Kenai rides the wave of regenerative medicine and cell therapy innovation, particularly iPSC-derived neurons for neurodegeneration, amid a Parkinson's market projected to grow due to aging populations and limited symptomatic treatments like levodopa.[1][2][3] Timing aligns with regulatory momentum for allogeneic therapies (e.g., FDA's RMAT designation potential) and manufacturing advances, favoring Kenai's off-the-shelf model over personalized cells.[2] Market forces include rising CNS disorder prevalence and investor interest in curative biotech, as seen in its Series A from specialized funds; Kenai influences the ecosystem by validating iPSC for Parkinson's, potentially accelerating adoption in ALS, Huntington's, and beyond via partnerships like Gateway Labs.[1][3][4]
Kenai is poised for clinical milestones in 2025, including RNDP-001 Phase 1/2 data readouts and IND submissions, leveraging its San Diego hub for expansion into genetic Parkinson's programs.[1][4] Trends like AI-optimized iPSC manufacturing and combo therapies with gene editing will shape its path, amplifying influence as a leader in neuron replacement amid biotech's shift to functional cures. With strong funding and preclinical proof, Kenai could redefine neurological treatment paradigms, building on its stealth-to-clinical momentum for long-term patient impact.[2][3]